ReviewESC heart failure2018
Mitral valve interventions in heart failure.
Review in ESC heart failure, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 53 citations in OpenAlex.
- Case Report: Transthoracic echocardiographic diagnosis of agenesis of mitral chordae tendineae with papillary muscle fusion.Frontiers in cardiovascular medicine · 2026Article
- Free Margin Running Suture Repair for Bileaflet Mitral Valve Prolapse in Patients with Left Ventricular Dysfunction: A Mid-term Follow-up Study.Interdisciplinary cardiovascular and thoracic surgery · 2025Article
- Mitral valve replacement versus repair for severe mitral regurgitation in patients with reduced left ventricular ejection fraction.JTCVS open · 2024Article
- Development and validation of a prediction model for heart failure in patients with heart valvular regurgitation.ESC heart failure · 2024Article
- Substantial challenge for a patient with severe mitral regurgitation and pulmonary hypertension undergoing transcatheter mitral valve edge-to-edge repair procedure.Journal of anesthesia and translational medicine · 2024Article
- Characteristics and Outcomes of Patients Ineligible for Transcatheter Mitral Valve Replacement.Structural heart : the journal of the Heart Team · 2023Article
- Structural Interventions in Heart Failure: Mending a Broken Heart.Journal of clinical medicine · 2023Review
- Clinical Utility of Three-Dimensional Echocardiography in the Evaluation of Mitral Valve Disease: Tips and Tricks.Journal of clinical medicine · 2023Review
- Percutaneous reduction of septal-to-lateral mitral annular distance to increase mitral leaflet coaptation length: Preclinical study results.JTCVS techniques · 2023Article
- Pathophysiology and Management of Heart Failure in the Elderly.The International journal of angiology : official publication of the International College of Angiology, Inc · 2022Article
- Do Not Withhold Mitral Surgery from Patients with Poor Left Ventricular Function.Medicina (Kaunas, Lithuania) · 2022Article
- Percutaneous Mitral Valve Repair in Patients with Severe Mitral Regurgitation and Acute Decompensated Heart Failure.Journal of clinical medicine · 2021Article
- Long-term clinical and haemodynamic results after transcatheter annuloplasty for secondary mitral regurgitation.ESC heart failure · 2021Article
- Multimodality Imaging in Transcatheter Mitral Interventions.Frontiers in cardiovascular medicine · 2021Review
- Heart failure in the last year: progress and perspective.ESC heart failure · 2020Review
- Impact of Subclinical Congestion on Outcome of Patients Undergoing Mitral Valve Surgery.Biomedicines · 2020Article
- Muscle Wasting and Sarcopenia in Heart Failure-The Current State of Science.International journal of molecular sciences · 2020Review
- Ischemic Mitral Regurgitation: Current Understanding and Surgical Options.Indian journal of thoracic and cardiovascular surgery · 2020Article
- The Choice of Treatment in Ischemic Mitral Regurgitation With Reduced Left Ventricular Function.The Annals of thoracic surgery · 2019Review
- The difference in referencing in Web of Science, Scopus, and Google Scholar.ESC heart failure · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secondary mitral regurgitation (MR) results from left ventricular dilatation and dysfunction. Quantification of secondary MR is challenging because of the underlying myocardial disease. Clinical and echocardiographic evaluation requires a multi-parametric approach. Severe secondary MR occurs in up to one-fourth of patients with heart failure with reduced ejection fraction, which is associated with a mortality rate of 40% to 50% in 3 years. Percutaneous edge-to-edge mitral valve repair (MitraClip) has emerged as an alternative to surgical valve repair to improve symptoms, functional capacity, heart failure hospitalizations, and cardiac haemodynamics. Further new transcatheter strategies addressing MR are evolving. The Carillion, Cardioband, and Mitralign devices were designed to reduce the annulus dilatation, which is a frequent and important determinant of secondary MR. Several transcatheter mitral valve replacement systems (Tendyne, CardiAQ-Edwards, Neovasc, Tiara, Intrepid, Caisson, HighLife, MValve System, and NCSI NaviGate Mitral) are emerging because valve replacement might be more durable compared with valve repair. In small studies, these interventional therapies demonstrated feasibility and efficiency to reduce MR and to improve heart failure symptoms. However, neither transcatheter nor surgical mitral valve repair or replacement has been proven to impact on the prognosis of heart failure patients with severe MR, which remains high with a mortality rate of 14-20% at 1 year. To date, the primary indication for treatment of secondary severe MR is the amelioration of symptoms, reinforcing the value of a Heart Team discussion. Randomized studies to investigate the treatment effect and long-term outcome for any transcatheter or surgical mitral valve intervention compared with optimized medical treatment are urgently needed and underway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.